Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit. The introduction of dual peroxisome proliferator-activated receptors agonist has provided a new insight into the management of both diabetes and dyslipidemia.
Aim and Objective: Hence, this study aimed to compare the effect of saroglitazar and pioglitazone on the lipid parameters and glycemic profile in patients of diabetes mellitus with dyslipidemia.
Materials and Methods: Adult patients with diabetic mellitus with dyslipidemia fulfilling the inclusion criteria were included in the study. One group received saroglitazar (4 mg/day) and the other group received pioglitazone (15 mg/day). Lipid parameters; triglyceride (TG), low-density lipoprotein, high-density lipoprotein (HDL), and serum cholesterol levels and glycemic parameters; fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycosylated hemoglobin (HbA1C) were measured at baseline and month 3, 6, and 12.
Results: Significant improvement seen in TG and HDL level at month 12 from baseline in both the treatment groups but saroglitazar was more effective than pioglitazone (P < 0.05). FPG, PPPG, and HbA1C were also reduced significantly from the baseline at the end of the study period (P < 0.05). Both the drugs were not associated with any sever adverse drug reactions.
Conclusion: The current study showed that saroglitazar was more effective than pioglitazone in controlling lipid and glycemic parameters in diabetic patients with dyslipidemia.
Diabetes Mellitus; Glycemic Parameters; Dyslipidemia